Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DCOYBullishIndustry Newsnews

High materiality8/10

Decoy’s D-MAVs Show Filovirus Potency; PRV Pathway Could Drive Non-Dilutive Funding

Sep 22, 2026, 8:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive signal from preclinical efficacy, coupled with potential PRV monetization and non-dilutive funding, could attract alts buyers and bridge financings; however, no near-term approval exists, so upside is contingent on funding and regulatory milestones.

AI summary

What happened, with direct paths to the underlying reporting

Decoy Therapeutics reports potent in vitro activity of D-MAVs against Ebola Zaire and Marburg, advancing a pan-filovirus program via the FDA Animal Rule. The company is pursuing non-dilutive government grants and partnerships to monetize its PRV opportunities, with potential deals historically ranging $100–$180 million. A successful path could shorten timelines and broaden the biodefense pipeline without equity dilution.

D-MAVs show potent in vitro activity against Ebola Zaire and Marburg. Company explores pan-filovirus program under FDA Animal Rule.
First-gen candidate: low-micromolar IC50 against Ebola Zaire. >5x improvement vs pan-coronavirus lead; 7x vs remdesivir.
PRV eligibility could unlock non-dilutive capital. Recent PRV deals ranged $100–$180M.
Aim: pan-filovirus D-MAV for pre- and post-exposure prophylaxis. Engineered for extended tissue residence; weekly dosing possible.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Decoy’s D-MAVs Show Filovirus Potency; PRV Pathway Could Drive Non-Dilutive Funding

Decoy Therapeutics secures up-to-$21M PIPE to push lead asset into trials